Japan Tissue Engineering Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,032M | ¥2,514M | ¥2,455M | ¥2,183M |
| Gross Profit | ¥1,137M | ¥1,691M | ¥1,511M | ¥1,267M |
| Operating Income | -¥728M | ¥145M | -¥238M | -¥549M |
| Pretax Income | -¥728M | ¥145M | -¥238M | -¥549M |
| Net Income | -¥729M | ¥143M | -¥255M | -¥735M |
| EPS | -¥17.96 | ¥3.53 | -¥6.29 | -¥18.09 |
| Operating Margin | -35.82% | 5.75% | -9.71% | -25.17% |
| Balance Sheet | ||||
| Total Assets | ¥6,883M | ¥6,989M | ¥6,513M | ¥5,683M |
| Total Equity | ¥5,937M | ¥6,080M | ¥5,825M | ¥5,090M |
| Total Liabilities | ¥946M | ¥908M | ¥688M | ¥593M |
| Cash | ¥4,135M | ¥4,266M | ¥3,885M | ¥3,250M |
| Interest-bearing Debt | ¥0M | ¥0M | - | - |
| Equity Ratio | 86.25% | 87.00% | 89.44% | 89.57% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥623M | ¥274M | -¥148M | -¥488M |
| Investing CF | ¥1,125M | -¥242M | -¥233M | ¥253M |
| Financing CF | -¥1M | -¥0M | -¥0M | - |
| Free CF | -¥799M | ¥1M | -¥242M | -¥566M |
| Efficiency | ||||
| ROE | -12.28% | 2.35% | -4.38% | -14.43% |
| ROA | -10.60% | 2.05% | -3.92% | -12.93% |
Latest IR Information
-
First Quarter Financial Results for Fiscal Year Ending March 2027 | Details of Revenue and Profit
J・TEC achieved an increase in revenue and operating profit in the first quarter of fiscal year ending March 2027. Revenue is unknown, and operating profit was 240 million yen, up YoY. Contributions from significant growth in Jack OA, successful in-house...
Read more -
Financial Summary for the First Quarter of Fiscal Year Ending March 2027【Japan GAAP】 (Unaudited, Non-Consolidated)
Sales for the first quarter of fiscal year ending March 2027 reached 76.6 billion yen (YoY +80.3%), net income was 5.2 billion yen (YoY +21.7%). Revenue significantly increased driven by strong growth in the medical business.
Read more -
Q1 FY2026 Financial Results Explanation Material
Sales for the first quarter of Fiscal Year 2026 increased by 130% YoY, operating profit turned positive, and net assets grew to approximately 510 billion yen. Continued expansion of new products and businesses strengthens the growth foundation.
Read more -
Notice of Establishment of Subsidiary in the Federal Republic of Germany
Read more -
Notice Regarding the Establishment of a Subsidiary in the Federal Republic of Germany
Read more
Latest News (5 items)
Company Information
About
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Lab Site Project segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it offers EPI-MODEL, a reconstructed human epidermis model. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.
